EIDX insider filings
Eidos Therapeutics, Inc. — 24 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2021-01-28. Screen EIDX transaction legs live →
Insider transaction summary — last 90 days
No insider filings (Forms 3/4/5) for EIDX between 2026-08-23 and 2026-11-21. The table below lists the most recent filings on record.
Recent insider filings — Eidos Therapeutics, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2021-01-28 | 4 | Turtle Cameron — Chief Business Officer | Code (U): 50,699 · Disposition to issuer (D): 9,469 (derivative) · Disposition to issuer (D): 53,157 (derivative) | EDGAR |
| 2021-01-28 | 4 | Sinha Uma — Chief Scientific Officer | Gift (G): 3,000 @ $0 · Code (U): 303,525 · Disposition to issuer (D): 60,000 (derivative) | EDGAR |
| 2021-01-28 | 4 | Valle Franco — Senior Vice President, Finance | Disposition to issuer (D): 24,350 (derivative) | EDGAR |
| 2021-01-28 | 4 | Fox Jonathan C — See Remarks | Gift (G): 500 @ $0 · Code (U): 380,467 · Disposition to issuer (D): 70,000 (derivative) | EDGAR |
| 2021-01-28 | 4 | Satvat Ali J. — Director | Disposition to issuer (D): 21,528 (derivative) · Disposition to issuer (D): 21,528 (derivative) · Disposition to issuer (D): 43,056 (derivative) | EDGAR |
| 2021-01-28 | 4 | Lis William — Director | Disposition to issuer (D): 21,528 (derivative) · Disposition to issuer (D): 21,528 (derivative) · Disposition to issuer (D): 43,056 (derivative) | EDGAR |
| 2021-01-28 | 4 | Hooper Suzanne Sawochka — Director | Disposition to issuer (D): 21,447 (derivative) · Disposition to issuer (D): 4,526 (derivative) | EDGAR |
| 2021-01-28 | 4 | Rohlen Douglas — Director | Disposition to issuer (D): 21,447 (derivative) · Disposition to issuer (D): 4,526 (derivative) | EDGAR |
| 2021-01-26 | 4 | BridgeBio Pharma, Inc. — 10% owner | Purchase (P): 14,428,836 | EDGAR |
| 2021-01-15 | 4 | Sinha Uma — Chief Scientific Officer, Director | Sale (S): 696 @ $121.11 · Sale (S): 572 @ $122.27 · Sale (S): 1,498 @ $123.48 · Sale (S): 4,934 @ $124.72 · Sale (S): 2,000 @ $125.35 · Sale (S): 300 @ $126.39 | EDGAR |
| 2021-01-13 | 4 | Valle Franco — Senior Vice President, Finance | Option exercise (M): 1,500 @ $7.24 · Sale (S): 1,500 @ $125.61 · Option exercise (M): 1,747 @ $7.24 · Sale (S): 1,747 @ $125.44 · Option exercise (M): 1,500 (derivative) @ $0 · Option exercise (M): 1,747 (derivative) @ $0 | EDGAR |
| 2020-12-16 | 4 | Turtle Cameron — Chief Business Officer | Option exercise (M): 4,451 @ $17 · Option exercise (M): 21,843 @ $13.20 · Sale (S): 3,756 @ $110.29 · Sale (S): 7,600 @ $111.31 · Sale (S): 11,445 @ $112.19 · Sale (S): 3,493 @ $112.97 · +2 more | EDGAR |
| 2020-12-04 | 4 | Sinha Uma — Chief Scientific Officer, Director | Sale (S): 3,798 @ $89.63 · Sale (S): 702 @ $90.63 · Sale (S): 300 @ $91.89 · Sale (S): 200 @ $92.97 | EDGAR |
| 2020-11-13 | 4 | Turtle Cameron — Chief Business Officer | Sale (S): 3,005 @ $73.56 · Sale (S): 9,497 @ $74.75 · Sale (S): 908 @ $75.23 · Gift (G): 1,500 @ $0 | EDGAR |
| 2020-11-10 | 4 | Valle Franco — Senior Vice President, Finance | Option exercise (M): 1,623 @ $7.24 · Sale (S): 1,623 @ $74.93 · Option exercise (M): 1,623 (derivative) @ $0 | EDGAR |
| 2020-11-03 | 4 | Turtle Cameron — Chief Business Officer | Option exercise (M): 5,000 @ $13.20 · Option exercise (M): 2,500 @ $17 · Sale (S): 9,145 @ $70.44 · Sale (S): 3,146 @ $71.42 · Sale (S): 209 @ $72.10 · Option exercise (M): 5,000 (derivative) @ $0 · +1 more | EDGAR |
| 2020-10-30 | 4 | Sinha Uma — Chief Scientific Officer, Director | Sale (S): 1,300 @ $71.90 · Sale (S): 3,700 @ $72.60 | EDGAR |
| 2020-10-09 | 4 | Valle Franco — Senior Vice President, Finance | Option exercise (M): 5,000 @ $7.24 · Sale (S): 5,444 @ $75.08 · Option exercise (M): 5,199 @ $7.24 · Sale (S): 5,199 @ $74.85 · Option exercise (M): 5,000 (derivative) @ $0 · Option exercise (M): 5,199 (derivative) @ $0 | EDGAR |
| 2020-10-02 | 4 | Sinha Uma — Chief Scientific Officer, Director | Sale (S): 69 @ $52.08 · Sale (S): 100 @ $52 · Sale (S): 4,831 @ $52.35 | EDGAR |
| 2020-09-18 | 4 | Fox Jonathan C — See Remarks | Sale (S): 5,767 @ $50.16 | EDGAR |
| 2020-09-16 | 4 | Fox Jonathan C — See Remarks | Sale (S): 111 @ $50 · Sale (S): 1,000 @ $50.06 · Sale (S): 3,122 @ $50.16 | EDGAR |
| 2020-09-11 | 4 | Turtle Cameron — Chief Business Officer | Option exercise (M): 2,500 @ $17 · Sale (S): 2,500 @ $47 · Option exercise (M): 2,500 (derivative) @ $0 | EDGAR |
| 2020-08-10 | 4 | Hooper Suzanne Sawochka — Director | Grant/award (A): 4,526 (derivative) @ $0 · Grant/award (A): 21,447 (derivative) @ $0 | EDGAR |
| 2020-08-10 | 4 | Rohlen Douglas — Director | Grant/award (A): 4,526 (derivative) @ $0 · Grant/award (A): 21,447 (derivative) @ $0 | EDGAR |
Recent 8-K events — Eidos Therapeutics, Inc.
Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2021-01-26 | 8-K | 1.01 — Entry into a Material Definitive Agreement 2.01 — Completion of Acquisition or Disposition of Assets 2.03 — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing 3.03 — Material Modification to Rights of Security Holders 5.01 — Changes in Control of Registrant 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 9.01 — Financial Statements and Exhibits | EDGAR |
| 2021-01-20 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2021-01-12 | 8-K | 8.01 — Other Events | EDGAR |
| 2020-10-29 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2020-10-07 | 8-K | 1.01 — Entry into a Material Definitive Agreement 9.01 — Financial Statements and Exhibits | EDGAR |
| 2020-10-05 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2020-09-29 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2020-08-07 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=EIDX returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs